A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

This study is looking at how well a new medicine called rocatinlimab helps people with moderate-to-severe asthma. Asthma is a condition that makes it hard to breathe because the airways in the lungs become narrow. If you are between 18 and 75 years old and have had asthma for over a year, you might be able to join. You should already be using some asthma treatments like inhaled corticosteroids (medicines you breathe in) and have had at least one asthma flare-up in the past year. However, you can't join if you've been in the hospital for asthma recently, have other lung diseases, or are currently smoking.

• The study involves taking doses of rocatinlimab and monitoring asthma symptoms.
• Participants will need to attend several visits over the study period.
• There might be compensation for participation.

Consider if you meet the study's requirements and can commit to the visits and treatments.